Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 37.18
ARQL's Cash to Debt is ranked higher than
77% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. ARQL: 37.18 )
ARQL' s 10-Year Cash to Debt Range
Min: 0.92   Max: No Debt
Current: 37.18

Equity to Asset 0.61
ARQL's Equity to Asset is ranked higher than
71% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. ARQL: 0.61 )
ARQL' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.93
Current: 0.61

-0.16
0.93
F-Score: 1
Z-Score: -6.32
M-Score: -3.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -228.84
ARQL's Operating margin (%) is ranked higher than
63% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -57.52 vs. ARQL: -228.84 )
ARQL' s 10-Year Operating margin (%) Range
Min: -790.25   Max: 4.14
Current: -228.84

-790.25
4.14
Net-margin (%) -223.97
ARQL's Net-margin (%) is ranked higher than
63% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.49 vs. ARQL: -223.97 )
ARQL' s 10-Year Net-margin (%) Range
Min: -582.35   Max: 7.66
Current: -223.97

-582.35
7.66
ROE (%) -42.40
ARQL's ROE (%) is ranked higher than
67% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -27.70 vs. ARQL: -42.40 )
ARQL' s 10-Year ROE (%) Range
Min: -141.91   Max: 4.84
Current: -42.4

-141.91
4.84
ROA (%) -26.17
ARQL's ROA (%) is ranked higher than
70% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -20.88 vs. ARQL: -26.17 )
ARQL' s 10-Year ROA (%) Range
Min: -44.05   Max: 3.4
Current: -26.17

-44.05
3.4
ROC (Joel Greenblatt) (%) -2309.48
ARQL's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -212.10 vs. ARQL: -2309.48 )
ARQL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1610.71   Max: 6.14
Current: -2309.48

-1610.71
6.14
Revenue Growth (%) -27.60
ARQL's Revenue Growth (%) is ranked higher than
65% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ARQL: -27.60 )
ARQL' s 10-Year Revenue Growth (%) Range
Min: -61.3   Max: 44.2
Current: -27.6

-61.3
44.2
EBITDA Growth (%) -16.40
ARQL's EBITDA Growth (%) is ranked higher than
69% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. ARQL: -16.40 )
ARQL' s 10-Year EBITDA Growth (%) Range
Min: -45.5   Max: 143.8
Current: -16.4

-45.5
143.8
EPS Growth (%) -16.90
ARQL's EPS Growth (%) is ranked higher than
71% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ARQL: -16.90 )
ARQL' s 10-Year EPS Growth (%) Range
Min: -48.4   Max: 132.1
Current: -16.9

-48.4
132.1
» ARQL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ARQL Guru Trades in Q3 2013

Chuck Royce 60,000 sh (New)
Jean-Marie Eveillard 3,314,553 sh (-26.47%)
Jim Simons 221,183 sh (-61.49%)
» More
Q4 2013

ARQL Guru Trades in Q4 2013

Paul Tudor Jones 17,323 sh (New)
Chuck Royce 160,000 sh (+166.67%)
Jean-Marie Eveillard 2,843,599 sh (-14.21%)
Jim Simons 80,638 sh (-63.54%)
» More
Q1 2014

ARQL Guru Trades in Q1 2014

Jim Simons 262,583 sh (+225.63%)
Chuck Royce 200,000 sh (+25%)
Jean-Marie Eveillard 2,843,599 sh (unchged)
Paul Tudor Jones 15,323 sh (-11.55%)
» More
Q2 2014

ARQL Guru Trades in Q2 2014

George Soros 78,600 sh (New)
Jim Simons 1,102,168 sh (+319.74%)
Paul Tudor Jones 15,323 sh (unchged)
Chuck Royce 200,000 sh (unchged)
Jean-Marie Eveillard 2,843,599 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARQL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 New Buy$1.34 - $2.04 $ 1.15-26%78600
Jean-Marie Eveillard 2013-09-30 Reduce -26.47%0.01%$2.15 - $2.79 $ 1.15-54%3314553
Jean-Marie Eveillard 2012-12-31 Add 49.46%0.01%$2.18 - $2.95 $ 1.15-56%4539651
Jean-Marie Eveillard 2012-06-30 Add 28.79%0.01%$5.53 - $8.16 $ 1.15-82%2673589
George Soros 2011-12-31 Sold Out 0.0014%$4.58 - $6.05 $ 1.15-79%0
George Soros 2011-09-30 Add 54.79%$4.11 - $6.64 $ 1.15-78%16100
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.50
ARQL's P/B is ranked higher than
94% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.62 vs. ARQL: 1.50 )
ARQL' s 10-Year P/B Range
Min: 1.38   Max: 111.17
Current: 1.5

1.38
111.17
P/S 6.20
ARQL's P/S is ranked higher than
85% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.28 vs. ARQL: 6.20 )
ARQL' s 10-Year P/S Range
Min: 1.71   Max: 102.75
Current: 6.2

1.71
102.75
EV-to-EBIT -0.51
ARQL's EV-to-EBIT is ranked higher than
65% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARQL: -0.51 )
ARQL' s 10-Year EV-to-EBIT Range
Min: 102.5   Max: 223.1
Current: -0.51

102.5
223.1
Current Ratio 3.05
ARQL's Current Ratio is ranked higher than
69% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. ARQL: 3.05 )
ARQL' s 10-Year Current Ratio Range
Min: 1.06   Max: 12.74
Current: 3.05

1.06
12.74
Quick Ratio 3.05
ARQL's Quick Ratio is ranked higher than
71% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. ARQL: 3.05 )
ARQL' s 10-Year Quick Ratio Range
Min: 1.06   Max: 12.74
Current: 3.05

1.06
12.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.33
ARQL's Price/Net Cash is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 100.00 vs. ARQL: 2.33 )
ARQL' s 10-Year Price/Net Cash Range
Min: 1.47   Max: 645.83
Current: 2.33

1.47
645.83
Price/Net Current Asset Value 2.33
ARQL's Price/Net Current Asset Value is ranked higher than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 45.54 vs. ARQL: 2.33 )
ARQL' s 10-Year Price/Net Current Asset Value Range
Min: 1.42   Max: 214
Current: 2.33

1.42
214
Price/Tangible Book 1.52
ARQL's Price/Tangible Book is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. ARQL: 1.52 )
ARQL' s 10-Year Price/Tangible Book Range
Min: 0.57   Max: 95.33
Current: 1.52

0.57
95.33
Price/Median PS Value 0.70
ARQL's Price/Median PS Value is ranked higher than
92% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.80 vs. ARQL: 0.70 )
ARQL' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 9.13
Current: 0.7

0.09
9.13
Earnings Yield (Greenblatt) 0.40
ARQL's Earnings Yield (Greenblatt) is ranked higher than
50% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. ARQL: 0.40 )
ARQL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 1
Current: 0.4

0.4
1
Forward Rate of Return (Yacktman) -51.39
ARQL's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -11.47 vs. ARQL: -51.39 )
ARQL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -38.6   Max: -6.1
Current: -51.39

-38.6
-6.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AQL.Germany
ArQule, Inc. was incorporated in Delaware. The Company is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employ technologies such as its ArQule Kinase Inhibitor Platform ('AKIP') to design and develop drugs that have the potential to fulfill this mission. Its product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing. Its product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase. C-Met is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. The Company and its partners, Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') and Kyowa Hakko Kirin Co., Ltd. ('Kyowa Hakko Kirin'), are implementing a clinical development program designed to realize the broad potential of tivantinib as a well-tolerated single agent and in combination with other anti-cancer therapies in a number of disease indications The Company has licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. Its proprietary pipeline is directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers. The advanced candidates in this pipeline are ARQ 087, an inhibitor of fibroblast growth factor receptor, ARQ 621, an inhibitor of the Eg5 kinesin motor protein, and ARQ 736, an inhibitor of the RAF kinases, all of which are in Phase 1 clinical testing. Its drug discovery efforts are engaged mainly on AKIP, which it is using to generate compounds designed to inhibit kinases without competing with adenosine triphosphate ('ATP') for binding to the target kinase, as well as other types of kinase inhibitors. ATP is a chemical found in all living cells and is the energy source involved in a variety of physiological processes. The Company faces competition from pharmaceutical companies, biotechnology companies and academic and research organizations. The Company's product candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA in the United States and by comparable authorities in other countries.
» More Articles for ARQL

Headlines

Articles On GuruFocus.com
comment on ARQL Nov 29 2012 
ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
cooldecency99 note on ARQL May 01 2010 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
ArQule Reports Second Quarter 2009 Financial Results Aug 06 2009 
ArQule, Inc. to Report Second Quarter 2009 Financial Results on Thursday, August 6, 2009 Jul 30 2009 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 2,500 Shares May 15 2009 

More From Other Websites
ARQULE INC Financials Aug 19 2014
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Costs Associated with... Aug 05 2014
Q2 2014 ArQule, Inc. Earnings Release - 07:00 am ET Aug 05 2014
ArQule Reports Second Quarter 2014 Financial Results Aug 05 2014
ArQule to Report Second Quarter 2014 Financial Results on August 5, 2014 Jul 29 2014
ARQULE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 30 2014
ArQule Announces Data Presentations with Tivantinib to Be Featured at ASCO 2014 May 30 2014
ArQule Inc. (ARQL) in Focus: Stock Rises 8.21% May 30 2014
ArQule to Present at Jefferies Global Healthcare Conference May 29 2014
Washington Prime Group, NOW, Civeo Set to Join S&P MidCap 400; UTi Worldwide, General Cable,... May 22 2014
UTi Worldwide to replace ArQule in S&P 600 as of 5/28 close May 22 2014
ARQULE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 16 2014
ArQule Posts Narrower-than-Expected Q1 Loss May 08 2014
ArQule's (ARQL) CEO Paolo Pucci on Q1 2014 Results - Earnings Call Transcript May 07 2014
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 07 2014
Arqule (ARQL) Q1 2014 Results - Earnings Call Webcast May 07 2014
ArQule Reports First Quarter 2014 Financial Results May 07 2014
ArQule to Report First Quarter 2014 Financial Results on May 7, 2014 Apr 30 2014
ArQule, Inc. to Present at Needham 13th Annual Healthcare Conference Apr 02 2014
ArQule's Loss Narrows in Q4 Mar 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK